Since Affimed N.V. (NASDAQ:AFMD) and EyeGate Pharmaceuticals Inc. (NASDAQ:EYEG) are part of the Biotechnology industry, they are influenced by compare. The influences particularly affect the dividends, analyst recommendations, profitability, risk, earnings and valuation, institutional ownership of both companies.
Valuation and Earnings
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|EyeGate Pharmaceuticals Inc.||N/A||3.08||N/A||-0.19||0.00|
Table 1 demonstrates Affimed N.V. and EyeGate Pharmaceuticals Inc.’s top-line revenue, earnings per share and valuation.
Table 2 represents Affimed N.V. (NASDAQ:AFMD) and EyeGate Pharmaceuticals Inc. (NASDAQ:EYEG)’s net margins, return on assets and return on equity.
|Net Margins||Return on Equity||Return on Assets|
|EyeGate Pharmaceuticals Inc.||0.00%||-69.3%||-48.4%|
Volatility & Risk
Affimed N.V.’s 2.79 beta indicates that its volatility is 179.00% more volatile than that of S&P 500. Competitively, EyeGate Pharmaceuticals Inc. is 99.00% more volatile than S&P 500, because of the 1.99 beta.
The current Quick Ratio of Affimed N.V. is 3.2 while its Current Ratio is 3.2. Meanwhile, EyeGate Pharmaceuticals Inc. has a Current Ratio of 7.2 while its Quick Ratio is 7.2. EyeGate Pharmaceuticals Inc. is better positioned to pay off its short-term and long-term debts than Affimed N.V.
Ratings and Recommendations for Affimed N.V. and EyeGate Pharmaceuticals Inc. can be find in next table.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|EyeGate Pharmaceuticals Inc.||0||0||0||0.00|
$8 is Affimed N.V.’s consensus target price while its potential upside is 183.69%.
Insider and Institutional Ownership
The shares of both Affimed N.V. and EyeGate Pharmaceuticals Inc. are owned by institutional investors at 41.7% and 40.1% respectively. 8.15% are Affimed N.V.’s share owned by insiders. Competitively, insiders own roughly 4.5% of EyeGate Pharmaceuticals Inc.’s shares.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|EyeGate Pharmaceuticals Inc.||-7.15%||-14.35%||-23.52%||-57.85%||-61.04%||-55.6%|
For the past year Affimed N.V.’s stock price has smaller decline than EyeGate Pharmaceuticals Inc.
Affimed N.V. beats on 6 of the 8 factors EyeGate Pharmaceuticals Inc.
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in Germany and internationally. Its lead candidate is AFM13, a natural killer cell (NK-cell) TandAb designed for the treatment of CD30-positive (CD30+) B- and T-cell malignancies, including Hodgkin lymphoma. The companyÂ’s product candidates include AFM24, a NK-cell that treats epidermal growth factor receptor expressing solid tumors, such as lung, head, neck, and colon cancers; AFM26, which binds to B-cell maturation antigen (BCMA) for the treatment of multiple myeloma; and Trispecific Abs for the treatment of multiple myeloma. Its product candidates also comprise AFM11, a T-cell TandAb, which is in Phase I clinical trial for the treatment of various CD19+ B-cell malignancies, including non-Hodgkin Lymphoma and acute lymphocytic leukemia; and AMV564, a CD33/CD3-specific T-cell TandAb for the treatment of acute myeloid leukemia and other hematologic malignancies. The company has license agreements with Amphivena Therapeutics, Inc., Deutsches Krebsforschungszentrum, and Xoma Ireland Limited; research funding agreement with The Leukemia & Lymphoma Society; and collaboration with Merck Sharp & Dohme B.V. It also has a clinical development and commercialization collaboration with The University of Texas MD Anderson Cancer Center to evaluate AFM13 in combination with MD AndersonÂ’s NK-cell product. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.
EyeGate Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing drug compositions and drug delivery systems for treating diseases and disorders of the eye. The company is developing EGP-437 for the treatment of various inflammatory conditions of the eye, including the treatment of ocular inflammation and pain in post-surgical cataract patients; and uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea. It is also developing the EyeGate Ocular Bandage Gel, a topically-applied eye drop formulation that has completed its first-in-man clinical trial for the management of corneal epithelial defects, as well as to accelerate re-epithelization of the ocular surface following surgery, injection, and other traumatic and non-traumatic conditions. In addition, the company is developing Eyegate II drug delivery system. It has license agreements with the University of Miami and its School of Medicine; subsidiaries of Valeant Pharmaceuticals International, Inc.; BioTime, Inc.; and the University of Utah Research Foundation. Eyegate Pharmaceuticals, Inc. is headquartered in Waltham, Massachusetts.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.